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Abstract 
Objective: Adverse event reports (AERs) submitted to the US Food and Drug Admin-
istration (FDA) were reviewed to confirm the platinum agent-associated mild, severe, 
and lethal hypersensitivity reactions.  
Methods: Authorized pharmacovigilance tools were used for quantitative signal detec-
tion, including the proportional reporting ratio, the reporting odds ratio, the information 
component given by a Bayesian confidence propagation neural network, and the empir-
ical Bayes geometric mean. Excess2, given by the multi-item gamma Poisson Shrinker 
algorithm, was used to evaluate the effects of dexamethasone and diphenhydramine on 
oxaliplatin-induced hypersensitivity reactions. 
Results: Based on 1,644,220 AERs from 2004 to 2009, carboplatin and oxaliplatin proved 
to cause mild, severe, and lethal hypersensitivity reactions, whereas cisplatin did not. 
Dexamethasone  affected  oxaliplatin-induced  mild  hypersensitivity  reactions,  but  had 
lesser effects on severe and lethal reactions. The effects of diphenhydramine were not 
confirmed. 
Conclusion:  The  FDA’s  adverse  event  reporting  system,  AERS,  with  optimized  data 
mining tools is useful to authorize potential associations between platinum agents and 
hypersensitivity reactions. 
Key words: adverse event, AERS, platinum agent, hypersensitivity 
Introduction 
The treatment of metastatic colorectal cancer has 
progressed significantly over the past 20 years, and 
currently the FOLFIRI or FOLFOX regimen [1-4], with 
or  without  a  targeted  monoclonal  antibody,  is  the 
standard treatment [5-8], consisting of the injection of 
a bolus of 5-fluorouracil (5-FU), irinotecan or oxali-
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platin (L-OHP), and the infusion of 5-FU/leucovorin, 
respectively. Future improvements will likely require 
the incorporation of or substitution with a novel an-
ticancer drug, personalization based on genetic pro-
filing, or pharmacokinetically-guided administration.  
Hypersensitivity  reactions  are  a  well-known 
complication of the use of the platinum agents, cis-
platin  (CDDP)  and  carboplatin  (CBDCA)  [9-12]. 
L-OHP, a third-generation platinum agent, has also 
been increasingly recognized to cause hypersensitiv-
ity reactions [13-16], but the incidence still varies in 
reports  [17-25].  It  is  difficult  to  evaluate  the  exact 
prevalence  of  these  reactions,  presumably  because 
their  definition  is  vast  and  pathogenic  mechanisms 
are still vague, but L-OHP-induced hypersensitivity 
can be classified into relatively acute severe anaphy-
laxes and delayed mild allergic reactions [13-16]. A 
reduction of the infusion rate and the administration 
of  steroids  and/or  antihistamines  are  used  to  treat 
both for acute and delayed hypersensitivity reactions, 
and  discontinuation  is  strongly  suggested  immedi-
ately upon the development of acute reactions [13-16]. 
However, large-scale validation is still awaited. 
In  this  study,  adverse  event  reports  (AERs) 
submitted to the US Food and Drug Administration 
(FDA)  were  reviewed  to  confirm  the  platinum 
agent-associated mild, severe, and lethal hypersensi-
tivity reactions. This data base relies on spontaneous 
reports to the FDA generated by health professionals, 
consumers, and manufacturers, and the system is re-
ferred  to  as  the  Adverse  Event  Reporting  System 
(AERS). The structure of AERS is in compliance with 
international  safety  reporting  guidance,  ICH  E2B. 
Recently, the AERS database has been used for eval-
uation of safety profiles of statins [26-29], rofecoxib 
[30], topical bovine thrombin [31] and infliximab [32]. 
Here,  the  effects  of  dexamethasone  and  diphenhy-
dramine  on  L-OHP-induced  reactions  were  also 
evaluated to suggest a management strategy for pa-
tients with hypersensitivity reactions. The effects of 
bevacizumab,  often  used  with  L-OHP,  were  also 
evaluated. 
Methods 
The AERS database covers several million case 
reports on adverse events. Pharmacovigilance analy-
sis aims to search for previously unknown patterns 
and  automatically  detect  important  signals,  i.e., 
drug-associated  adverse  events,  from  such  a  large 
database.  Recently  developed  data  mining  tools  for 
pharmacovigilance have been successful at detecting 
signals  that  could  not  be  found  by  individual  case 
reviews  and  that  warrant  further  investigation  to-
gether with continuous surveillance. For this reason, 
data mining tools are being routinely used for phar-
macovigilance, supporting signal detection and deci-
sion-making at companies, regulatory agencies, and 
pharmacovigilance centers [33-39]. Despite some lim-
itations inherent to spontaneous reporting, the AERS 
database is a rich resource and the data mining tools 
described below provide a powerful means of identi-
fying  potential  associations  between  drugs  and  ad-
verse events.  
Data sources 
Input  data for  this  study  were  taken from  the 
public  release  of  the  FDA’s  AERS  database,  which 
covers  the  period  from  the  first  quarter  of  2004 
through the end of 2009. The database consists of 7 
data  sets;  patient  demographic  and  administrative 
information  (DEMO),  drug/biologic  information 
(DRUG),  adverse  events  (REAC),  patient  outcomes 
(OUTC),  report  sources  (RPSR),  drug  therapy  start 
and  end  dates  (THER),  and  indications  for 
use/diagnosis  (INDI).  The  adverse  events  in  REAC 
are coded using preferred terms (PTs) in the Medical 
Dictionary  for  Regulatory  Activities  (MedDRA)  ter-
minology. 
Prior  to  analysis,  all  drug  names  were  unified 
into  generic  names  by  a  text-mining  approach,  be-
cause AERS permits the registering of arbitrary drug 
names, including trade names and abbreviations. For 
the  batch  conversion  of  drug  names,  reliable  drug 
databases, e.g., FDA Orange Book, were utilized as a 
dictionary.  Spelling  errors  were  detected  by  GNU 
Aspell and carefully confirmed by working pharma-
cists. Furthermore, drug names which failed to receive 
generic  names  were  manually  converted  to  proper 
names. Foods, beverages, treatments (e.g. X-ray radi-
ation),  and  unspecified  names  (e.g.,  beta-blockers) 
were omitted for this study. Duplicated reports were 
deleted  according  to  FDA's  recommendation  of 
adopting the most recent CASE number (as described 
in one of the downloaded files, 'Asc_nts.doc' from the 
web-site of the FDA AERS database), resulting in the 
reduction of the number of AERs from 2,231,029 to 
1,644,220. 
Definition of adverse events 
According  to  the  National  Cancer  Institute 
Common  Terminology  Criteria  for  Adverse  Events 
(NCI-CTCAE)  v4.0,  AERs  with  PT10020751/ 
hypersensitivity in REAC were adopted as the reports 
on mild hypersensitivity reactions, in which 19 lower 
level terms (LLTs) were assigned in MedDRA v13.0, 
including  LLT10000656/acute  allergic  reaction, 
LLT10001718/allergic  reaction,  LLT10020756/ 
hypersensitivity  reaction,  LLT10020759/ Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
334 
hypersensitivity  symptom,  LLT10038195/red  neck 
syndrome, and LLT10046305/upper respiratory tract 
hypersensitivity  reaction  (site  unspecified).  AERs 
with PT10011906/death (with 13 LLT) or death terms 
in  OUTC  were  excluded  for  mild  hypersensitivity 
reactions. AERs with PT10002198/anaphylactic reac-
tion were adopted as the reports on severe hypersen-
sitivity  reactions,  in  which  13  LLTs  were  assigned, 
including  LLT10000663/acute  anaphylactic  reaction 
and  LLT10002218/anaphylaxis.  AERs  both  with 
PT10020751, and PT10011906 or death terms in OUTC 
were adopted as the reports on lethal hypersensitivity 
reactions. Of note, LLT10001718/allergic reaction and 
LLT10002218/anaphylaxis  are  assigned  as  allergic 
reactions  and  anaphylaxis  in  the  NCI-CTCAE  v4.0, 
respectively, and PTs in their higher levels were used 
in this study. 
Data mining 
In pharmacovigilance analysis, data mining al-
gorithms  have  been  developed  to   identify 
drug-associated  adverse  events  as  signals  that  are 
reported more frequently than expected by estimating 
expected reporting frequencies on the basis of infor-
mation  on  all  drugs  and  all  events  in  the  database 
[37-39]. For example, the proportional reporting ratio 
(PRR) [33], the reporting odds ratio (ROR) [34], the 
information component  (IC)  [35], and  the  empirical 
Bayes geometric mean (EBGM) [36] are widely used, 
and indeed, the PRR is currently used by the Medi-
cines  and  Healthcare  products  Regulatory  Agency 
(MHRA), UK, the ROR by the Netherlands Pharma-
covigilance Centre, the IC by the World Health Or-
ganization (WHO), and the EBGM by the FDA. 
All of these algorithms extract decision rules for 
signal detection and/or  calculate scores to measure 
the  associations  between  drugs  and  adverse  events 
from a two-by-two frequency table of counts that in-
volve the presence or absence of a particular drug and 
a  particular  event  occurring  in  case  reports.  These 
algorithms, however, differ from one another in that 
the  PRR  and  ROR  are  frequentist  (non-Bayesian), 
whereas the IC and EBGM are Bayesian. In this sec-
tion, only the scoring thresholds used in the present 
study are given, and the reader is referred to review 
articles for details [37-39]. 
For  the  PRR,  a  given  drug-adverse  event  pair 
was defined as a signal, if the event count ≥ 3, and the 
PRR ≥ 2.0 with an associated chi-square value ≥ 4.0 
[33], and for the ROR, if the lower bound of the 95% 
two-sided confidence interval (CI) of ROR exceeded 1 
[34]. For the IC, IC025, a criterion indicating the lower 
bound of the 95% two-sided CI of the IC, was adopt-
ed, and a IC025 value exceeding 0 was defined as a 
signal [35]. Lastly, for the EBGM, EB05 ≥ 2.0 was set as 
a threshold for signal detection, where EB05 is inter-
preted as a lower one-sided 95% confidence limit of 
EBGM [36]. 
The AERS database is also a valuable resource 
for  exploring  drug-drug  interactions.  Here,  we  are 
interested in  how  the  co-administration  of  dexame-
thasone, diphenhydramine, and bevacizumab would 
affect  L-OHP-induced  mild,  severe,  and  lethal  hy-
persensitivity  reactions,  although  the  database  does 
not  provide  the  information  on  the  timing  of 
co-administration. To analyze such interactions, case 
reports  on  L-OHP  were  classified  according  to 
whether they also involved one of the three drugs. 
Any association among the interactions was then as-
sessed using Excess2, a statistical index of the mul-
ti-item  gamma  Poisson  shrinker  (MGPS)  algorithm 
[36]. 
Results 
AERs in which CDDP, CBDCA, or L-OHP was 
the principal offending agent are summarized in Ta-
bles 1-3, and numbered 44,321, 39,653, and 33,194 of 
1,644,220, respectively. Reports of mild, severe, and 
lethal  hypersensitivity  reactions  numbered  43,288, 
18,225, and 2,397, respectively.  
CBDCA was administered in 229 of 43,288 AERs 
of mild, 72 of 18,225 AERs of severe, and 12 of 2,397 
AERs  of  lethal  hypersensitivity  reactions  (Table  2). 
L-OHP was administered in 126, 60 and 10, respec-
tively (Table 3). The signals were detected for CBDCA 
and L-OHP by either the PRR, ROR, IC or EBGM, but 
no  signal  was  suggested  for  CDDP  (Table  1).  The 
sensitivity was higher for ROR or IC, whereas lower 
for EBGM.  
The effects of the co-administration of dexame-
thasone on L-OHP-induced hypersensitivity reactions 
are summarized in Table 4. The values obtained with 
Excess2 were 18.66, 1.19 and -0.44, respectively, indi-
cating that dexamethasone was more effective against 
mild  than  severe  or  lethal  reactions.  The  effects  of 
diphenhydramine were also examined, but no signal 
was  detected  (data  not  shown).  The  data  on  the 
co-administration of bevacizumab is listed in Table 5. 
Values of Excess2 were 0.28, 5.38 and -5.65, respec-
tively,  and  suggesting  an  effect  of  bevacizumab  on 
severe L-OHP-induced reactions. 
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Table 1. Signal detection for CDDP-associated mild, severe and lethal hypersensitivity reactions 
  Mild  Severe  Lethal 
  43,288  18,225  2,397 
No.of AERs  38  29  5 
       
PRR 
(kai2) 
0.436 
(27.256) 
0.790 
(1.412) 
1.036 
(0.022) 
       
ROR 
(95% two-sided CI) 
0.435 
(0.317, 0.553) 
0.790 
(0.549, 1.031) 
1.036 
(0.431, 1.641) 
       
IC 
(95% two-sided CI) 
-1.195 
(-1.651, -0.739) 
-0.353 
(-0.875, 0.169) 
-0.081 
(-1.287, 1.125) 
       
EBGM 
(95% one-sided CI) 
0.441 
(0.337) 
0.781 
(0.574) 
0.907 
(0.455) 
Total number of adverse event reports (AERs) accompanied with CDDP administration was 44,321. Reports of mild, severe and lethal hy-
persensitivity reactions numbered 43,288, 18,225 and 2,397, respectively. PRR: the proportional reporting ratio [33], ROR: the reporting odds 
ratio [34], IC: the information component [35], EBGM: the empirical Bayes geometric mean [36]. There was no signal for CDDP-associated 
mild, severe and lethal hypersensitivity reactions (see “Methods” for the criteria of detection). 
 
Table 2. Signal detection for CBDCA-associated mild, severe and lethal hypersensitivity reactions 
  Mild  Severe  Lethal 
  43,288  18,225  2,397 
No.of AERs  229  72  12 
       
PRR 
(kai2) 
2.949 * 
(291.792) 
2.196 * 
(45.698) 
2.780 * 
(11.975) 
       
ROR 
(95% two-sided CI) 
2.959 * 
(2.598, 3.320) 
2.201 * 
(1.746, 2.656) 
2.789 * 
(1.582, 3.996) 
       
IC 
(95% two-sided CI) 
1.539 * 
(1.352, 1.726) 
1.100 * 
(0.767, 1.433) 
1.233 * 
(0.432, 2.034) 
       
EBGM 
(95% one-sided CI) 
2.880 * 
(2.580) 
2.097 
(1.723) 
2.079 
(1.288) 
Total number of adverse event reports (AERs) accompanied with CBDCA administrations was 39,653. Reports of mild, severe and lethal 
hypersensitivity reactions numbered 43,288, 18,225 and 2,397, respectively. PRR: the proportional reporting ratio [33], ROR: the reporting 
odds ratio [34], IC: the information component [35], EBGM: the empirical Bayes geometric mean [36]. *: signal detected, see “Methods” for 
the criteria of detection. 
 
Table 3. Signal detection for L-OHP-associated mild, severe and lethal hypersensitivity reactions 
  Mild  Severe  Lethal 
  43,288  18,225  2,397 
No.of AERs  126  60  10 
       
PRR 
(kai2) 
1.934 
(55.797) 
2.186 * 
(37.412) 
2.768 * 
(9.604) 
       
ROR 
(95% two-sided CI) 
1.937 * 
(1.626, 2.248) 
2.190 * 
(1.699, 2.681) 
2.775 * 
(1.491, 4.059) 
       
IC 
(95% two-sided CI) 
0.933 * 
(0.681, 1.185) 
1.087 * 
(0.723, 1.451) 
1.187 * 
(0.312, 2.062) 
       
EBGM 
(95% one-sided CI) 
1.888 
(1.628) 
2.070 
(1.669) 
1.983 
(1.178) 
Total number of adverse event reports (AERs) accompanied with L-OHP administrations was 33,194. Reports of mild, severe and lethal 
hypersensitivity reactions numbered 43,288, 18,225 and 2,397, respectively. PRR: the proportional reporting ratio [33], ROR: the reporting 
odds ratio [34], IC: the information component [35], EBGM: the empirical Bayes geometric mean [36]. *: signal detected, see “Methods” for 
the criteria of detection. 
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Table 4. Effect of co-administration of dexamethasone on L-OHP-associated hypersensitivity reactions 
  L-OHP  dexamethasone  Hypersensitivity  Excess2 
yes  no 
Mild  yes  yes  40  4,774  18.66 
  yes  no  469  172,768   
  no  yes  1,884  924,995   
  no  no  132,784  184,631,220   
           
Severe  yes  yes  13  4,801  1.19 
  yes  no  214  173,023   
  no  yes  919  925,960   
  no  no  53,827  184,710,177   
           
Lethal  yes  yes  6  4,808  -0.44 
  yes  no  54  173,183   
  no  yes  393  926,486   
  no  no  13,287  184,750,717   
The numbers of L-OHP-associated hypersensitivity reactions are listed. The interaction was assessed using Excess2, a statistical index of the 
multi-item gamma Poisson shrinker (MGPS) algorithm [36]. The data suggested that dexamethasone affected mild L-OHP-induced hyper-
sensitivity reactions, but had lesser effects on severe and lethal reactions. 
 
Table 5. Effect of co-administration of bevacizumab on L-OHP-associated hypersensitivity reactions 
  L-OHP  bevacizumab  Hypersensitivity  Excess2 
yes  no 
Mild  yes  yes  35  11,943  0.28 
  yes  no  286  200,959   
  no  yes  474  165,599   
  no  no  134,382  185,355,256   
           
Severe  yes  yes  20  11,958  5.38 
  yes  no  103  201,142   
  no  yes  207  165,866   
  no  no  54,643  185,434,995   
           
Lethal  yes  yes  4  11,974  -5.65 
  yes  no  45  201,200   
  no  yes  56  166,017   
  no  no  13,635  185,476,003   
The numbers of L-OHP-associated hypersensitivity reactions are listed. The interaction was assessed using Excess2, a statistical index of the 
multi-item gamma Poisson shrinker (MGPS) algorithm [36]. The data suggested that bevacizumab possibly affected severe L-OHP-induced 
hypersensitivity reactions. 
 
Discussion 
Although the exact mechanism by which plati-
num agents cause hypersensitivity reactions remains 
unclear, the agents are thought to induce a type I re-
sponse mediated by IgE, followed by the release of 
histamine and cytokines, since reactions usually occur 
after multiple infusions [13-16]. Recent studies have 
suggested the involvement of a type IV reaction, i.e., 
T-cell-mediated production of cytokines, such as tu-
mor necrosis factor-alpha and interleukin-6, especially 
for CDDP and CBDCA [13-16]. As far as L-OHP is 
concerned, most reactions are thought to be of type I, 
but reports of hemolysis and thrombocytopenia sug-
gest a type II reaction, and chronic urticaria, joint pain 
and proteinuria can be attributed to a type III reaction 
[13-16].  The  incidence  of  hypersensitivity  reactions 
varies  in  reports,  and  this  study  was  conducted  to 
confirm the platinum agent-associated  mild, severe, 
and lethal hypersensitivity reactions. Here, using an 
extremely  large  number  of  AERs  submitted  to  the 
FDA with authorized data mining tools, CBDCA and Int. J. Med. Sci. 2011, 8 
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L-OHP proved to cause mild, severe, and lethal hy-
persensitivity reactions, whereas CDDP did not. 
Spontaneous reports of suspected adverse events 
are  a  valuable  tool.  However,  this  database  has  its 
limitations  [37].  First,  the  data  occasionally  contain 
misspelling and miswords, although the structure of 
AERS is in compliance with the international safety 
reporting guidance. Second, the system was started 
more than 10 years ago, and reporting patterns have 
changed  over  time.  Third,  the  adverse  events  are 
coded  using hierarchical terms of PTs of MedDRA, 
and changes in terminology over time also might af-
fect  the  quality  of  the  database.  Last,  there  are  a 
number of duplicate entries in the database. To over-
come problems with data quality, we manually cor-
rected mistakes in the data entities and deleted du-
plicates according to FDA’s recommended method. A 
long-term discussion on pharmacovigilance strategies 
with large numbers of spontaneous reports resulted in 
the quantitative signal detection indices PRR, ROR, IC 
and  EBGM.  Comparisons  in  terms  of  specificity 
showed that none of these indices is universally better 
than the others [34, 37, 38], but EBGM is of lowest 
sensitivity in this study (Tables 2, 3).  
Since  1998,  the  FDA  has  been  exploring  the 
MGPS program, which evaluates the signals for pairs 
and higher-order [35]. This program is used to detect 
possible synergistic interactions between drugs, i.e., 
drug-drug interaction. With an index of Excess2, the 
effects  of  dexamethasone  and  diphenhydramine  on 
L-OHP-induced  hypersensitivity  reactions  were 
evaluated  to  suggest  the  best  patient  management 
strategy. It was suggested that the co-administration 
of dexamethasone affected mild L-OHP-induced re-
actions  more  effectively,  than  severe  or  lethal  reac-
tions (Table 4). Here, the effects of diphenhydramine 
were  not  confirmed,  but  unexpectedly,  it  was  sug-
gested  that  bevacizumab  affected  L-OHP-induced 
severe reactions. It is noted that the database does not 
provide  the  information  on  the  timing  of 
co-administration. Additionally, we do not have the 
criteria, e.g., threshold value, of Excess2 to detect an 
unknown drug-drug interaction, and the calibration 
using many known drug-drug interactions would be 
necessary. 
In conclusion, AERs submitted to the FDA were 
reviewed  to  confirm  the  platinum  agent-associated 
mild,  severe,  and  lethal  hypersensitivity  reactions. 
Authorized  pharmacovigilance  tools  were  used  for 
quantitative signal detection, and the effects of dexa-
methasone and diphenhydramine on L-OHP-induced 
hypersensitivity reactions were also evaluated. Based 
on  1,644,220  AERs  from  2004  to  2009,  CBDCA  and 
L-OHP proved to cause mild, severe, and lethal hy-
persensitivity  reactions,  whereas  CDDP  did  not. 
Dexamethasone  affected  L-OHP-induced  mild  hy-
persensitivity reactions, but had lesser effects on se-
vere and lethal reactions. 
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